FDA Approves Arsenic Trioxide for Promyelocytic Leukemia

January 16, 2018 – The FDA has approved arsenic trioxide in combination with the all-trans retinoic acid (ATRA) agent tretinoin for the treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia (APL) with the t(15;17) translocation or PML-RARA gene expression. The approval was based on published findings and a review of a global safety database for arsenic trioxide, according to Teva Pharmaceuticals, the company developing the … (leggi tutto)